Efficacy of Add-On Aldosterone Receptor Blocker in Uncontrolled Hypertension

American Journal of Hypertension

Volumn 19, Issue 7, 2006, Pages 750-755

  Sharabi, Yehonatan ^a,b   Adler, Eldad ^a   Shamis, Ari ^a   Nussinovitch, Naomi ^a   Markovitz, Avinoam ^a   Grossman, Ehud ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

aldosterone; potassium; renin; Spironolactone; uncontrolled hypertension

Indexed keywords

ALDOSTERONE RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HORMONE RECEPTOR BLOCKING AGENT; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; STANDARD; TREATMENT OUTCOME;

AGED; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; RECEPTORS, ALDOSTERONE; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 33745273601     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.11.016     Document Type: Article

References (31)

1. Kaplan N.M. Resistant hypertension. J Hypertens 23 (2005) 1441-1444
2. Martell N., Rodriguez-Cerrillo M., Grobbee D.E., Lopez-Eady M.D., Fernandez-Pinilla C., Avila M., Fernandez-Cruz A., and Luque M. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press 12 (2003) 149-154
3. Goodfriend T.L., and Calhoun D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone. theory and therapy. Hypertension 43 (2004) 518-524
4. Calhoun D.A., Nishizaka M.K., Zaman M.A., and Harding S.M. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125 (2004) 112-117
5. Kaplan N.M. The current epidemic of primary aldosteronism. causes and consequences. J Hypertens 22 (2004) 863-869
6. Fardella C.E., Mosso L., Gomez-Sanchez C., Cortes P., Soto J., Gomez L., Pinto M., Huete A., Oestreicher E., Foradori A., and Montero J. Primary hyperaldosteronism in essential hypertensives. prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
7. Lim P.O., Dow E., Brennan G., Jung R.T., and MacDonald T.M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 (2000) 311-315
8. Loh K.C., Koay E.S., Khaw M.C., Emmanuel S.C., and Young Jr. W.F. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85 (2000) 2854-2859
9. Mosso L., Carvajal C., Gonzalez A., Barraza A., Avila F., Montero J., Huete A., Gederlini A., and Fardella C.E. Primary aldosteronism and hypertensive disease. Hypertension 42 (2003) 161-165
10. Strauch B., Zelinka T., Hampf M., Bernhardt R., and Widimsky Jr. J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17 (2003) 349-352
11. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., and Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
12. Benchetrit S., Bernheim J., and Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 4 (2002) 17-20
13. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., and Lilledahl N.P. Low-renin status in therapy-resistant hypertension. a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
14. Vasan R.S., Evans J.C., Larson M.G., Wilson P.W., Meigs J.B., Rifai N., Benjamin E.J., and Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (2004) 33-41
15. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
16. Berecek K.H., Farag A., Bahtiyar G., Rothman J., and McFarlane S.I. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 6 (2004) 211-212
17. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., Sever P.S., and McG Thom S. Guidelines for management of hypertension. report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
18. Schwartz G.L., Chapman A.B., Boerwinkle E., Kisabeth R.M., and Turner S.T. Screening for primary aldosteronism. implications of an increased plasma aldosterone/renin ratio. Clin Chem 48 (2002) 1919-1923
19. Montori V.M., Schwartz G.L., Chapman A.B., Boerwinkle E., and Turner S.T. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 76 (2001) 877-882
20. Hood S., Cannon J., Foo R., and Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 5 (2005) 55-60
21. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., Cofield S., and Calhoun D.A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 18 (2005) 805-812
22. Plouin P.F., and Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits?. Eur J Endocrinol 151 (2004) 305-308
23. Siscovick D.S., Raghunathan T.E., Psaty B.M., Koepsell T.D., Wicklund K.G., Lin X., Cobb L., Rautaharju P.M., Copass M.K., and Wagner E.H. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330 (1994) 1852-1857
24. Stewart P.M. Mineralocorticoid hypertension. Lancet 353 (1999) 1341-1347
25. Hatakeyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., and Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269 (1994) 24316-24320
26. Rocha R., and Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970 (2002) 89-100
27. Blacher J., Amah G., Girerd X., Kheder A., Ben Mais H., London G.M., and Safar M.E. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 10 (1997) 1326-1334
28. Gomez-Sanchez E.P., Zhou M., and Gomez-Sanchez C.E. Mineralocorticoids, salt and high blood pressure. Steroids 61 (1996) 184-188
29. Nishizaka M.K., Zaman M.A., Green S.A., Renfroe K.Y., and Calhoun D.A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109 (2004) 2857-2861
30. Croom K.F., and Perry C.M. Eplerenone. a review of its use in essential hypertension. Am J Cardiovasc Drugs 5 (2005) 51-69
31. Hameedi A., and Chadow H.L. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Curr Hypertens Rep 2 (2000) 378-383